Uncategorized Archives - ARIZ Precision Medicine

Ariz Precision Medicine pitch earns $110,000 investment at AngelCon

November 23, 2024

A group of 13 newly minted angel investors put $110,000 into Davis-based Ariz Precision Medicine, a medical research startup developing nanotechnology cancer therapy drugs. https://www.bizjournals.com/sacramento/inno/stories/fundings/2024/11/21/ariz-precision-medicine-angelcon.html...

ARIZ and NATA Announce Collaboration to develop multiple targeted nucleic acid therapies for cancer treatment

DAVIS, CA, UNITED STATES, November 21, 2024 /EINPresswire.com/ -- The pioneering precision medicine company, ARIZ Precision Medicine (ARIZ), and the Medical Research Council’s Nucleic Acid Therapy Accelerator (NATA), today announced a collaboration to harness their platforms to develop nucleic acid...

ARIZ Announces Grant of Key US Patent

August 20, 2024

DAVIS, CALIFORNIA, UNITED STATES, August 20, 2024 /EINPresswire.com/ -- ARIZ Precision Medicine, Inc., a preclinical stage biopharmaceutical company developing precision ligand targeted siRNA cancer therapies, today announced the issuance of a broad patent for a highly specific drug candidate (ARIZ...

ARIZ Precision Medicine wins Golden Tickets to Bakar Labs, sponsored by BrightEdge/American Cancer Society

July 11, 2024

Congratulations to ARIZ Precision Medicine and Catena Biosciences, which have won Golden Tickets to Bakar Labs, sponsored by BrightEdge, the American Cancer Society’s impact investing, innovation, and venture capital arm! https://qb3.org/ariz-and-catena-awarded-golden-tickets-to-bakar-labs-spons...

ARIZ Precision Medicine adds H. Michael Shepard, PhD to the company’s scientific advisory board

June 24, 2022

https://www.einnews.com/pr_news/578338641/ariz-precision-medicine-adds-h-michael-shepard-phd-to-the-company-s-scientific-advisory-board...

ARIZ announces Seed round funding

November 3, 2020

ARIZ Precision Medicine, The PRDM Oncogene Targeting Company™ announced that it has secured seed financing bringing total funding to date of $2.5 million. Proceeds will be used to expand the management team as well as continue development of its proprietary PRDM-based product candidates for lung ca...

ARIZ Precision Medicine Announces Promotion of Brad Niles, Ph.D. to CEO Position

September 19, 2020

DAVIS, California —September 21, 2020-- ARIZ Precision Medicine (ARIZ) today announced the promotion of Brad Niles, Ph.D. to the Chief Executive Officer (CEO) position. Brad has previously served as ARIZ COO and VP of Research and Development since 2016. Former CEO Lonnie Bookbinder wil...

ARIZ completes CLSI FAST Advisory Program with a virtual Closing Showcase

August 7, 2020

http://califesciencesinstitute.org/fast-spring-2020-showcase-a-virtual-success/?utm_campaign=CLSA%20Bulletin&utm_medium=email&_hsmi=92289318&_hsenc=p2ANqtz-9oNCOUhD4NuhD9OTSKhtB6EROLGpBQC_Rji1gT1XSgGADIwHc6jUhCI4FBKszuX4QP3J69FMrLutp8y8UxCI_vFEmoyA&utm_content=92289318&utm_sour...

ARIZ Precision Medicine honored to participate in Johnson & Johnson Innovation’s Quick Pitch at JPM 2020

February 20, 2020

ARIZ Precision Medicine was honored to be selected as one of nine companies worldwide to participate in Johnson & Johnson Innovation’s Quick Pitch at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2020. ARIZ CEO Lonnie Bookbinder presented information abo...

Select Sacramento: Groundbreaking cancer research fueled by talent, funding and resources in Davis

April 18, 2019

We've been featured in an article on Select Sacramento. ARIZ Precision Medicine is pioneering cancer research out of their lab in Davis. They’re working to create a safer alternative to chemotherapy by developing a drug that targets cancer cells. ARIZ modulates cancer-causing genes and proteins...